16th July 2024

Consider the following statements regarding Wolbachia —

1. Wolbachia is a genus of bacteria that infects a wide range of insect species.
2. Wolbachia is used in biological control programs to reduce the population of disease-carrying mosquitoes.
3. The bacteria can directly kill the mosquitoes, thereby preventing the transmission of diseases.

Which of the above statements is/are correct?

Match List-I (Characteristic) with List-II (Ramsar Site) and select the correct answer using the code given below the Lists

List-I                                  List-II

1. Brackish water lagoon       1. Keoladeo National Park
2. High altitude wetland         2. Chilika Lake
3. Riverine wetland               3. Loktak Lake
4. Freshwater marsh             4. Tsomoriri

Code:

   A B C D

With reference to the National Geophysical Research Institute (NGRI), consider the following statements:

1. NGRI was established under the Ministry of Earth Sciences, Government of India.
2. The institute's research focus includes natural hazards like earthquakes and landslides.
3. NGRI's work on natural resources excludes the exploration of renewable energy sources.
4. The institute is headquartered in Dehradun, Uttarakhand.

Which of the statements given above are correct?

The e-FAST India initiative is supported by several knowledge partners. Which of the following is NOT a knowledge partner of e-FAST India?

Consider the following statements regarding the regulation and approval of weight loss drugs in India:

1. The Drugs Controller General of India (DCGI) has the sole authority to grant final approval for new drugs, including weight loss medications.
2. The Central Drugs Standard Control Organization (CDSCO) plays a role in reviewing recommendations from expert committees before final approval is granted.
3. Post-marketing surveillance (Phase IV trials) are mandatory for all newly approved weight loss drugs to monitor their long-term effects and safety.
4. Tirzepatide (brand name Zepbound) received expedited approval in India due to its proven efficacy in global trials, bypassing the need for Phase IV trials.

Which of the above statements are correct?